IRDiRC is delighted to present the outcome of the collaboration between the European Federation of Pharmaceutical Industries and Associations (EFPIA), the Rare Disease Moonshot and the IRDiRC Companies Constituent Committee: “The different contributions of the industry in Public-Private Partnerships in Rare Diseases Research continuum” report, which marks a pivotal moment in research advancement, innovation and treatment for RDs.
This new report highlights the unique value pharmaceutical and biotech companies bring to Public-Private Partnerships (PPPs).
Key takeaways:
Scientific & Regulatory Expertise
Companies provide cutting-edge infrastructure, data, technical know-how, and a deep understanding of regulatory pathways.
Operational Capacity
With a global footprint and strong project management skills, industry partners help scale innovations, manage risks, and drive efficient implementation.
Collaborative Leadership & Patient-Centric Approach
Industry actors know how to meaningfully engage patient organizations early in the R&D process, supporting co-creation of impactful solutions.
A Strategic Role in Rare Diseases
In a fragmented and resource-scarce field, industry involvement helps connect the dots, enrich efforts with real-world data, and accelerate impact.
Link to full report: https://lnkd.in/ej3Uccee